Adalank Side Effects: What the Evidence Actually Shows

REVIEWED BY

Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor

Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.

Adalank side effects — what the evidence actually shows

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-07

Adalank side effects have never been measured — not in a trial, a case report, or an animal study. Adalank is marketed as an analogue of Selank, the Russian anxiolytic heptapeptide, and that marketing does all the work: the compound has no published structure and no published study. What exists is Selank’s clinical literature, which listings quietly borrow. This page maps what that borrowed record contains when read for side effects, where it stops applying to a different molecule, and why “no reported side effects” describes the surveillance, not the compound.

Quick Answer: What the Adalank Side-Effect Data Actually Shows

There is no published safety data for Adalank — human, animal, or in vitro. Every side-effect claim attached to the name is a claim about Selank, a different peptide whose clinical record — comparative trials of 60 and 62 patients against benzodiazepines (PMID 25176261, PMID 18454096) — reports tolerability as scale scores and gives no adverse-event rates. Whether any of that transfers to Adalank is untested — nobody has published what Adalank is. Self-reported experiences from Reddit are summarized further down; they are anecdotes, not data.

★The Documented Experience: Zero Monitored Humans

On our cagrilintide and eloralintide pages, this box summarizes what hundreds of monitored trial participants went through. For Adalank the honest version is different: no human being has ever taken Adalank under study conditions where side effects were recorded. The nearest documented experience belongs to patients in Russian Selank trials — a different peptide, studied without a placebo arm, tolerability scored on rating scales rather than tallied as adverse events.

People do use Adalank — sprays and vials sell under the name. Their experiences exist; they have never been collected, controlled, or published. That is not a footnote to the safety picture — it is the safety picture.

When we publish an individual account here, it will be a real person, named with permission — like the reader experience on our hair-growth guide. We don’t write fiction into this slot.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is Adalank?

Adalank is a research-market peptide marketed as an analogue of Selank, the Russian anxiolytic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (PMID 30255741). That sentence is close to the entire verifiable file on Adalank: no published structure, no peer-reviewed study, no PubMed entry. Vendor listings borrow instead. Selank has a real clinical record, comparative trials against benzodiazepines in patients with anxiety disorders (PMID 25176261, PMID 18454096), and Adalank’s marketing assumes that record transfers. This page is about whether it does. Our Selank spray guide covers the parent compound’s sourcing side and our peptides for anxiety guide the wider class; here we stay on safety.

How It’s Thought to Work — Borrowed From Selank

Every mechanism claim about Adalank is a Selank claim wearing a different label. In radioligand studies, Selank acted as a positive allosteric modulator of [3H]GABA binding and could block the modulatory activity of diazepam and olanzapine (PMID 30255741). In rats, 1 hour after Selank or GABA at 300 μg/kg, 45 of 84 neurotransmission genes had changed expression, and 22 had at 3 hours (PMID 26924987). Separately, Selank dose-dependently inhibited plasma enkephalin breakdown with an IC50 of 15 microM (PMID 11550013). Whether any of this describes Adalank is untested: its modification is unpublished, and receptor behavior is exactly what modifications change. GABA-system modulation is also the benzodiazepines’ mechanism; the Selank papers list those drugs’ problems — dependence, memory impairment — and position the peptide as the “mild” alternative (PMID 30255741). Mildness in a paper’s framing is not mildness measured.

KEY TAKEAWAY

Adalank has no mechanism study. Everything said about how it works is inference from Selank — a GABA-allosteric, enkephalinase-inhibiting heptapeptide — and analogues diverge from their parent at the points where pharmacology is decided.

The Entire Evidence Base: Zero Adalank Studies

The complete published evidence base for Adalank: nothing. No clinical trial, animal experiment, in-vitro assay, pharmacokinetic study, or chemistry paper establishing what it is. The abstracts behind this page are all Selank papers — a 2001 enzyme study (PMID 11550013), Russian clinical comparisons published in 2008, 2014, and 2015 (PMID 18454096, PMID 25176261, PMID 26356395), rodent and cell work, and a 2020 fMRI study in 52 healthy participants (PMID 32342318). Set it beside eloralintide, whose page draws on placebo-controlled adverse-event tables, and “evidence base” becomes a scale rather than a checkbox — with Adalank at zero, alongside its cousin Adamax, marketed the same way off Semax.

The Side-Effect Dataset That Doesn’t Exist

A side-effect profile requires four things: people receiving the compound, a comparison group, systematic recording, and publication. Adalank has none of the four — no adverse-event table, no tolerability score, no case report. “No data” is literal here and runs both ways: nothing shows harm, nothing shows safety, and no study has posed the question. What makes Adalank’s gap sharper than AHK-Cu’s — a compound with at least one lab study of itself — is that the market supplied a ready-made substitute: Selank’s trials, pasted under a different name.

PERSONAL OBSERVATION — PI EDITORIAL

Reading Adalank listings beside the Selank abstracts, what struck us was how faithfully they reproduce Selank’s benefits and how completely they drop Selank’s context: psychiatric patients under clinical supervision, trials run by the group that developed the peptide, published in Russian, tolerability reported as a rating-scale result rather than an adverse-event table. A compound with zero studies is being sold on a summary of another compound’s studies — a summary missing exactly the parts a side-effects page needs.

What Selank’s Clinical Trials Recorded — and Didn’t

Here is the Selank human data, labeled as Selank throughout. In a 60-patient comparison against the benzodiazepine phenazepam in phobic-anxiety and somatoform disorders, Selank showed pronounced anxiolytic and mild nootropic effects, the anxiolytic effect lasted for a week after the last dose, and quality of life improved (PMID 25176261); the abstract says tolerability was studied and gives no adverse-event rates. In 62 patients with generalized anxiety disorder and neurasthenia, Selank (30 patients) and medazepam (32 patients) had similar anxiolytic effects, with Selank additionally showing antiasthenic and psychostimulant effects (PMID 18454096). A third Selank study gave 40 patients Selank plus phenazepam and 30 patients phenazepam alone, rating tolerability on the UKU scale: the combination reduced phenazepam’s undesirable effects — attention and memory impairment, asthenia, sedation, increased sleep duration, sexual disturbances, emotional indifference, and orthostatism — during treatment and after withdrawal (PMID 26356395). That is a list of a benzodiazepine’s side effects Selank reduced — not a list of Selank’s own.

Across all three Selank trials, the abstracts report no Selank-attributed adverse-event percentages, no discontinuations, and no placebo arm. The psychostimulant effect also deserves a flag: for a compound sold to calm people, an activating property cuts both ways. That record is the ceiling of what Adalank could inherit — and the inheritance is unproven.

Intranasal vs Injected: Why the Route Isn’t a Detail

Adalank is sold as a nasal spray and as lyophilized powder for injection; the Selank data say those are not interchangeable. In BALB/c mice given Selank at 300 μg/kg/day for 5 days, intraperitoneal Selank increased frontal-cortex GABA-receptor binding sites by 38% with no change at NMDA receptors, while intranasal Selank increased NMDA-receptor (MK-801) binding sites by 23% with no effect on GABA receptors — which the authors attributed to route-specific pharmacokinetics and biotransformation (PMID 29787664). Same peptide, different route, different receptor footprint; the clinical Selank abstracts do not specify route at all. For Adalank, none of this has been tested; the mouse work only shows that “same molecule either way” is false even for the parent.

PRACTICAL NOTES — STANDARD RESEARCH-SOLUTION HANDLING

  • Lyophilized peptides are reconstituted with bacteriostatic water; handling is the same for any research compound
  • No stability data exists for Adalank in solution or as a spray; storage assumptions are borrowed from other peptides
  • Nothing here is a dosing instruction; it is what research-use handling looks like on paper

Why “No Reported Side Effects” Isn’t “No Side Effects”

The commonest safety sentence about Adalank — “no side effects have been reported” — is technically true and structurally empty. Reporting requires a mechanism: trials with adverse-event logging, a pharmacovigilance system, published case reports. Adalank, unapproved and outside any clinical program, has none. A user who developed insomnia or nasal irritation tells a forum or nobody; neither reaches a literature search. Absence of evidence here is absence of surveillance, not surveillance returning a clean result. The one Selank sentence addressing side effects directly — that it “does not cause side effects typical of most anxiolytics” (PMID 11550013) — is a background assertion in a 2001 enzyme paper, not a measured result; and even that claim, from a group with clinical experience of the peptide, is lost in transfer to Adalank.

What Users Report: Self-Reported Effects From Reddit

With no study of Adalank in existence, the only descriptions of taking it are self-reports. We searched Reddit on September 4, 2026 and found 43 posts mentioning Adalank, almost all from 2026, and read the comment threads of the seven with any substance, across r/Peptides, r/BrainHackGuide, r/NooTopics, r/Selank and r/Nootropics. Everything below is paraphrased and linked, carries no usernames, and comes from anonymous people describing a product whose identity nobody verified. The most important finding is how little there is: most Adalank threads are people asking for experiences, not giving them, because the compound was hard to find for most of the year.

One detailed first-hand report exists, and it is a rave. In a 93-upvote r/Peptides thread, a poster took a single nasal pump before a job interview and described his anxiety dissolving within about fifteen minutes, calm plus focus, and declared it a possible replacement for benzodiazepines with no side effects, after one dose (thread). The replies are the useful part. The three most-upvoted responses were warnings: that a euphoric single-dose response is what habit-forming drugs feel like, that he should report back in a week, and that a compound described as non-habit-forming, side-effect-free and non-dependence-forming never turns out to be any of those things. One commenter who cycles subcutaneous N-acetyl Semax and N-acetyl Selank added that after two weeks off he felt he needed them to function, and that the non-habit-forming claim was, for him, nonexistent. Another said he uses Adamax, Selank and Semax at most one day a week each because tolerance builds quickly. A user claiming a decade of peptide use called Selank and Adalank weak compounds with small Russian studies behind them and attributed one-dose results to placebo.

No adverse effect attributed specifically to Adalank appeared in any thread we read. That is not reassurance. It reflects that almost nobody has described more than a first week of use. The adjacent Selank reports in the same threads are the nearest data: sleepiness (one user said Selank simply made him sleepy), a short duration that faded within a week in a poster who then planned to try Adalank to compensate (r/Biohackers), and a suggestion in an r/NooTopics thread to take Adamax by day and Adalank in the evening to wind down, which implies users expect it to be calming or sedating (thread).

Users do not agree on what Adalank is. In an r/BrainHackGuide explainer thread, one commenter stated flatly that Adalank is N-acetyl Selank amidate under another name; another objected that in the Semax family the acetylated-amidated form and Adamax are distinct products at very different prices, so the same should be true here (thread). A comparison thread noted that some people felt nothing from Adalank or the N-acetyl forms at all (r/NooTopics). If the people reporting cannot agree on the molecule, their reports describe a label, not a compound.

HOW TO READ SELF-REPORTS

Adalank’s Reddit record is one enthusiastic first dose and a chorus of experienced users predicting tolerance and dependence. Neither side has data. The single measurable fact is the shape of the conversation: dozens of people asking, one person answering, and the sixty-patient Selank studies above standing in for a compound they never tested.

Onset and Duration: What Selank’s Data Times

No Adalank data exists on when effects begin, peak, or fade, so any week-by-week side-effect calendar was invented. Selank supplies a few timing points, all for Selank: fMRI in 52 healthy participants detected connectivity changes between the right amygdala and right temporal cortex at 5 and 20 minutes after injection (PMID 32342318); in rats given Selank or GABA, the number of genes with altered expression fell from 45 at 1 hour to 22 at 3 hours (PMID 26924987); and in the 60-patient trial, Selank’s anxiolytic effect persisted for a week after the last dose (PMID 25176261). Those points time onset and persistence of benefit; none times a side effect, because none of the Selank abstracts reports one. For Adalank, the time course of everything is unmeasured.

Doses: What the Selank Studies Administered

The Selank abstracts name doses only in animals: 300 μg/kg in the rat gene-expression study (PMID 26924987) and 300 μg/kg/day for 5 days in the mouse route comparison (PMID 29787664). The clinical Selank abstracts do not state what patients received. Adalank has no dose data at any level, so every milligram figure on an Adalank listing has exactly one source: the vendor. Animal doses are reported as what the studies administered — not as anything transferable across species or compounds. For reconstitution arithmetic, our peptide calculator does the math and deliberately nothing else.

DID YOU KNOW

In a rat study, a course of the test substances shifted anxiety indicators toward deterioration even without chronic stress; Selank’s shift was less pronounced than diazepam’s, but it pointed the wrong way all the same (PMID 28280289).

Stacking Adalank: Interaction Data That Exists Only for Selank

Adalank combinations — with a benzodiazepine, with Semax or Adamax — have no published data. The Selank interaction literature is the nearest thing. In radioligand work, Selank and benzodiazepines jointly regulated GABA binding in a non-cumulative way that differed from either substance alone, and Selank could block the modulatory activity of diazepam and olanzapine (PMID 30255741). In neuroblastoma cells, Selank alone changed none of 84 GABAergic-system genes, but with olanzapine it altered more genes than olanzapine alone (PMID 28293190). In rats under chronic stress, diazepam plus Selank was the most effective anxiolytic combination (PMID 28280289); in patients, Selank add-on reduced phenazepam’s side effects (PMID 26356395). All Selank results, and together they say this peptide changes how other CNS drugs behave — not always in characterized ways. With no Adalank data at all, stacking multiplies the unknowns, not the benefits. Our Semax spray guide covers the other half of the usual pairing.

Where the Data Stops: The Research-Product Reality

With cagrilintide, the research-vial problem is that the vial doesn’t inherit the trials. With Adalank it runs deeper: there are no Adalank trials to inherit, and the trials being invoked belong to a different molecule. The gap shows up three ways: identity (with no published reference structure, even a clean batch-matched COA only confirms the product matches the vendor’s own specification), concentration arithmetic (reconstitution with bacteriostatic water is on the buyer), and no reference point — no “trial-grade Adalank experience” exists to compare against. Everything in this channel is sold strictly for non-human research use; for Adalank that label is not a disclaimer but the entire published record.

PERSONAL OBSERVATION — PI EDITORIAL

The strangest thing about covering Adalank is that the more we read about Selank, the less we knew about Adalank. Ten Selank papers later we can describe the parent’s receptor behavior, its route dependence in mice, and how three Russian trials scored it against benzodiazepines — none of it confirmed to apply to the compound in the listing. Our rule for pages like this: count the studies before trusting the adjectives. Here the count is zero, and every adjective was written about something else.

Sourcing and Verification

For a compound with no safety literature, product quality is the only safety variable anyone can influence. The checklist still applies: a batch-matched COA naming compound, quantity, and analytical method; independent third-party testing with a verifiable report number; and hard skepticism toward any listing quoting Selank findings under the Adalank name. Our guide to reading a certificate of analysis shows what a passing document looks like; our vendor reviews show who publishes one. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) We don’t track Adalank prices; when tested vendors stock a documented version, this section gets a table.

Regulatory Status: The US and the 2025 Medsafe Submission

Adalank is not an approved drug anywhere, has never been evaluated by the FDA, and has no registered clinical program — so no future readout will fill this page’s gaps. In the US it sits in the unreviewed research-chemical channel; our FDA research-chemical regulation guide covers that framework. The most concrete regulatory document on Adalank’s family is from New Zealand. In June 2025, Medsafe’s Investigation and Enforcement Team submitted “Classification of Unscheduled Peptides” to the Medicines Classification Committee, reporting that from 1 April 2025 to 19 May 2025, 56 parcels containing peptides or SARMs were intercepted at the border, that many peptides were not scheduled, and that products sold overseas “for research purposes only” were being imported for therapeutic use (Medsafe, June 2025). The submission devotes a section to tuftsin and its analogues — the class that includes Selank — and proposes group entries plus classification of listed individual peptides as prescription medicines, so importation without a prescription would not be permitted, “mitigating both the known and unknown clinical risks associated with them.” The excerpts we reviewed do not name Adalank; a compound with no published structure is hard to schedule by name. When that changes, so does this section.

Frequently Asked Questions

What are the side effects of Adalank?

Unknown — literally. No study of Adalank in humans, animals, or cells has been published, so no side-effect data exists. Every claim attached to the name is borrowed from Selank, and even Selank’s trial abstracts report no adverse-event rates.

Is Adalank the same as Selank?

No. Adalank is marketed as a Selank analogue, but no published structure or study says what the modification is or does. Selank is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro with a Russian clinical literature; Adalank has a name and a listing.

Is Adalank safe?

No published data answers that in either direction. Nothing documents harm; nothing demonstrates safety. Its reputation is inference from Selank, whose trials had no placebo arm and scored tolerability on rating scales.

Does Selank have side effects that might apply to Adalank?

Selank’s three clinical abstracts report no Selank-attributed adverse-event rates. The 62-patient GAD study noted a psychostimulant effect, and an add-on study found Selank reduced phenazepam’s side effects rather than adding its own. Whether any of that transfers to Adalank is untested.

Is Adalank nasal spray different from injectable Adalank?

For Adalank, nobody knows — no route has been studied. For Selank, a mouse study found intraperitoneal dosing raised GABA-receptor binding sites by 38% while intranasal dosing raised NMDA-receptor binding sites by 23%, each route leaving the other receptor unchanged.

What happens if Adalank is combined with benzodiazepines?

No data exists for Adalank in any combination. For Selank, radioligand studies showed a non-cumulative interaction with benzodiazepine modulation of GABA binding, and a patient study found Selank add-on reduced phenazepam’s side effects. Those are Selank findings, not Adalank data.

Glossary of Terms

  • Adalank: a research-market peptide marketed as an analogue of Selank; no published structure or study exists.
  • Selank: the Russian anxiolytic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, trialed against benzodiazepines; the source of every claim borrowed for Adalank.
  • Analogue: a compound structurally derived from a parent molecule; modifications can change stability, penetration, and receptor behavior, so the parent’s data does not transfer automatically.
  • Positive allosteric modulator: a substance that enhances a receptor’s response to its natural ligand by binding a secondary site — Selank’s effect on GABA binding in radioligand studies.
  • Enkephalinase: an enzyme that degrades enkephalins, the body’s opioid-like peptides; Selank inhibited plasma enkephalin breakdown.
  • UKU scale: a clinician-rated side-effect scale used in psychiatric trials; the tolerability instrument in the Selank-plus-phenazepam study.
  • COA (certificate of analysis): the lab document identifying a research vial’s contents; batch-matched or it proves nothing.

References